The hUC-MSCs are more suited for treating lung diseases than bone marrow and adipose-derived MSCs, because they are richer in CD146, a critical cell adhesion protein in blood vessels and endothelium, and exhibit superior functional characteristics, such as enhanced adhesion and proliferation rates, additionally, hUC-MSCs possess several notable advantages, including high activity, easy accessibility, rapid proliferation, and low immunogenicity, and have been increasingly reported for their therapeutic potential in the treatment of various diseases [19–21]. This evidence concerns the gene MCAM and lung disorder.